Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from November 30, 2023, to July 3, 2025, seeking damages for affected investors [1][2]. Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics for mast cell-driven diseases, including Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and Asthma [4]. - The lead product candidate, briquilimab, is a monoclonal antibody aimed at blocking the stem cell factor (SCF) from binding to the CD117 (c-Kit) receptor, which is believed to be crucial for mast cell survival [4]. Financial Developments - In 2024, Jasper completed an oversubscribed financing round of $50 million to strengthen its balance sheet and support briquilimab's development, extending its cash runway through the third quarter of 2025 [4]. - Following a press release on July 7, 2025, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share due to issues related to a drug product lot used in clinical studies [8]. Clinical Trials and Issues - Jasper commenced a Phase 1b/2a clinical study for CSU (BEACON Study) in November 2023 and another for allergic asthma (ETESIAN Study) in December 2024 [4]. - On July 7, 2025, Jasper reported that results from the BEACON Study were confounded by issues with a specific drug product lot, leading to the halting of the ETESIAN Study and a pause in development for asthma and SCID [8][10]. Management and Operational Changes - Following the announcement of the drug lot issues, Jasper revealed a corporate reorganization, including a workforce reduction of approximately 50% and the halting of other clinical and preclinical programs to focus on briquilimab in chronic urticaria [10].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Jasper To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 Â (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept. ...

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from November 30, 2023, to July 3, 2025, seeking damages for affected investors [1][2]. Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing therapeutics for mast cell-driven diseases, including Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU), and Asthma [4]. - The lead product candidate, briquilimab, is a monoclonal antibody aimed at blocking the stem cell factor (SCF) from binding to the CD117 (c-Kit) receptor, which is believed to deplete mast cells and provide clinical benefits for patients [4]. Financial Developments - In 2024, Jasper completed an oversubscribed financing round of $50 million to strengthen its balance sheet and support briquilimab's development, extending its cash runway through the third quarter of 2025 [4]. - Following a press release on July 7, 2025, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share due to issues related to a drug product lot used in clinical studies [8]. Clinical Trials and Issues - Jasper commenced a Phase 1b/2a clinical study for CSU (BEACON Study) in November 2023 and another for allergic asthma (ETESIAN Study) in December 2024 [4]. - On July 7, 2025, Jasper reported that results from the BEACON Study were confounded by issues with a specific drug product lot, leading to the halting of the ETESIAN Study and a pause in asthma development [8]. Management and Operational Changes - On July 9, 2025, Jasper announced a corporate reorganization, reducing its workforce by approximately 50% and halting other clinical and preclinical programs to focus on briquilimab in chronic urticaria [10]. - The Chief Medical Officer, Edwin Tucker, is set to depart from his role effective August 1, 2025 [10]. Legal Allegations - The lawsuit alleges that Jasper's executives made materially false and misleading statements regarding the company's operations and compliance with manufacturing regulations, which increased risks to the company's financial and clinical prospects [6][7].

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its business operations and compliance policies during the Class Period from November 30, 2023, to July 3, 2025 [2][3]. Allegation Details - The lawsuit claims that Jasper lacked necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the regulatory prospects of its products, particularly briquilimab [3]. - The failure to maintain proper manufacturing controls increased the likelihood of cost-reduction measures and overstated the Company's business and financial prospects [3]. Next Steps - Investors who purchased Jasper shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON JASPER THERAPEUTICS, INC. (JSPR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happen. ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN JASPER THERAPEUTICS, INC. (JSPR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal. ...

LOS ANGELES--(BUSINESS WIRE)---- $JSPR--Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR. ...

NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Why:Â Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"). ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON JASPER THERAPEUTICS, INC. (JSPR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On July 7, 2025, Jasper released an update on its Phas. ...

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, Briquilimab, which has resulted in significant stock price decline [1][2][3]. Group 1: Allegations and Issues - The lawsuit claims that Jasper Therapeutics failed to disclose critical information about its manufacturing controls and procedures, which were necessary to ensure compliance with cGMP regulations [2]. - This lack of disclosure allegedly increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, including Briquilimab [2]. - The failure to maintain proper controls also raised the likelihood of disruptive cost-reduction measures, leading to overstated business and financial prospects for the company [2]. Group 2: Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decrease, closing at $3.04 per share [3]. Group 3: Class Action Participation - Shareholders of Jasper Therapeutics may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiffs [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].